Palvella Therapeutics (PVLA) Other Accumulated Expenses: 2013-2024
Historic Other Accumulated Expenses for Palvella Therapeutics (PVLA) over the last 8 years, with Sep 2024 value amounting to $1.0 million.
- Palvella Therapeutics' Other Accumulated Expenses rose 79.30% to $1.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.0 million, marking a year-over-year increase of 79.30%. This contributed to the annual value of $169,000 for FY2023, which is 65.01% down from last year.
- Per Palvella Therapeutics' latest filing, its Other Accumulated Expenses stood at $1.0 million for Q3 2024, which was up 1.78% from $1.0 million recorded in Q2 2024.
- Palvella Therapeutics' 5-year Other Accumulated Expenses high stood at $1.0 million for Q3 2024, and its period low was $169,000 during Q4 2023.
- Its 3-year average for Other Accumulated Expenses is $592,818, with a median of $581,000 in 2022.
- As far as peak fluctuations go, Palvella Therapeutics' Other Accumulated Expenses slumped by 67.23% in 2020, and later soared by 252.60% in 2022.
- Palvella Therapeutics' Other Accumulated Expenses (Quarterly) stood at $347,000 in 2020, then rose by 13.26% to $393,000 in 2021, then increased by 22.90% to $483,000 in 2022, then plummeted by 65.01% to $169,000 in 2023, then soared by 79.30% to $1.0 million in 2024.
- Its Other Accumulated Expenses was $1.0 million in Q3 2024, compared to $1.0 million in Q2 2024 and $335,000 in Q1 2024.